Erschienen in:
01.07.2016 | Research Article
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
verfasst von:
J. De Castro, J. L. González-Larriba, S. Vázquez, B. Massutí, J. M. Sanchez-Torres, M. Dómine, P. Garrido, A. Calles, A. Artal, R. Collado, R. García, M. Sereno, M. Majem, J. A. Macías, O. Juan, J. Gómez-Codina, B. Hernández, M. Lázaro, A. L. Ortega, M. Cobo, J. M. Trigo, E. Carcereny, C. Rolfo, S. Macia, J. Muñoz, P. Diz, M. Méndez, F. Rosillo, L. Paz-Ares, J. V. Cardona, D. Isla
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
Background/Aim
First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.
Patients and methods
This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.
Results
Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.
Conclusion
Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.